<DOC>
	<DOCNO>NCT00052299</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Monoclonal antibody locate cancer cell either kill deliver cancer-killing substance without harm normal cell . It yet know combine combination chemotherapy monoclonal antibody therapy kill cancer cell . PURPOSE : Randomized phase III trial determine effectiveness combination chemotherapy without gemtuzumab ozogamicin treat patient acute myeloid leukemia .</brief_summary>
	<brief_title>Chemotherapy With Without Gemtuzumab Ozogamicin Treating Older Patients With Acute Myeloid Leukemia</brief_title>
	<detailed_description>OBJECTIVES : - Determine antileukemic activity standard induction chemotherapy without gemtuzumab ozogamicin elderly patient previously untreated acute myeloid leukemia . - Determine overall survival patient treat regimen . - Determine rate response , disease-free survival , event-free survival , incidence relapse , incidence death patient treat regimen . - Determine rate , type , grade toxicity regimens patient . OUTLINE : This randomize , open-label , multicenter study . Patients stratify accord age ( 61-69 v 70-75 ) , CD33 positivity ( le 5 % vs 5-19 % vs 20-80 % vs 80 % vs unknown ) , initial WBC hydroxyurea administration need ( less 30,000/mm^3 v least 30,000/mm^3 ) , participate center . Patients randomize 1 2 treatment arm . - Arm I : - Induction ( phase I ) : Patients receive gemtuzumab ozogamicin IV 2 hour day 1 15 . - Induction ( phase II/MICE regimen ) : Beginning day 50 53 , patient receive mitoxantrone IV 30 minute day 1 , 3 , 5 ; etoposide IV 1 hour day 1-3 ; cytarabine IV continuously day 1-7 . Bone marrow evaluation perform day 29 . Patients partial remission ( PR ) receive second course MICE chemotherapy regimen . Patients complete remission ( CR ) 1 2 course MICE regimen proceed consolidation therapy . Patients progressive disease go therapy . - Consolidation : Beginning within 4 week documentation CR , patient receive gemtuzumab ozogamicin IV 2 hour day 0 ; idarubicin IV day 1 , 3 , 5 ; etoposide IV 1 hour day 1-3 ; cytarabine IV continuously day 1-5 . After least day 30 , patient receive second consolidation course absence disease progression unacceptable toxicity . - Arm II : - Induction ( MICE regimen ) : Patients receive mitoxantrone , etoposide , cytarabine arm I induction . Bone marrow evaluation perform day 29 . Patients PR receive second course MICE chemotherapy regimen . Patients CR 1 2 course MICE regimen proceed consolidation therapy . Patients progressive disease go therapy . - Consolidation : Patients receive idarubicin , etoposide , cytarabine arm I consolidation . Patients follow monthly 1 year , every 3 month 2 year , every 6 month thereafter . PROJECTED ACCRUAL : A total 450 patient ( 225 per treatment arm ) accrue study within 3.75 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Idarubicin</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<mesh_term>Gemtuzumab</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis acute myeloid leukemia ( AML ) Bone marrow blast least 20 % bone marrow aspiration biopsy FAB subtypes M0M2 M4M7 No acute promyelocytic leukemia ( FAB subtype M3 ) Previously untreated primary secondary AML , include AML myelodysplastic syndrome Hydroxyurea and/or corticosteroid therapy 14 day allow No blast crisis chronic myelogenous leukemia No AML supervene myeloproliferative disease No active CNS leukemia PATIENT CHARACTERISTICS : Age 61 75 Performance status WHO 02 Life expectancy Not specify Hematopoietic WBC le 30,000/mm^3 ( pretreatment hydroxyurea 14 day allow ) Hepatic Bilirubin great 3 time upper limit normal ( ULN ) Renal Creatinine great 3 time ULN Cardiovascular No concurrent severe cardiovascular disease No arrhythmia require chronic treatment No congestive heart failure No symptomatic ischemic heart disease Pulmonary No severe pulmonary dysfunction ( CTC grade 34 ) Other HIV negative No uncontrolled infection No concurrent malignant disease No severe concurrent neurological psychiatric disease No prior alcohol abuse No psychological , familial , sociological , geographical condition would preclude study participation PRIOR CONCURRENT THERAPY : Biologic therapy No concurrent hematopoietic growth factor ( filgrastim [ GCSF ] sargramostim [ GMCSF ] ) except lifethreatening infection due neutropenia Chemotherapy See Disease Characteristics Endocrine therapy See Disease Characteristics Radiotherapy Not specify Surgery Not specify Other No prior enrollment trial</criteria>
	<gender>All</gender>
	<minimum_age>61 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>adult acute monocytic leukemia ( M5b )</keyword>
	<keyword>adult acute erythroid leukemia ( M6 )</keyword>
	<keyword>adult acute megakaryoblastic leukemia ( M7 )</keyword>
	<keyword>adult acute minimally differentiate myeloid leukemia ( M0 )</keyword>
	<keyword>adult acute myeloblastic leukemia maturation ( M2 )</keyword>
	<keyword>adult acute myeloblastic leukemia without maturation ( M1 )</keyword>
	<keyword>adult acute myelomonocytic leukemia ( M4 )</keyword>
	<keyword>adult acute monoblastic leukemia ( M5a )</keyword>
	<keyword>untreated adult acute myeloid leukemia</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
</DOC>